"Good medicine note" 11 drugs piled up over the review, a number of billions of varieties in the column; Zhengda Qing core hepatitis B drug, stone drug heavy antidepressants, Fosun, Haizheng, Xinhua ...

Guide: Consistency evaluation week dynamics! As of July 31, there were 2,249 CDE acceptance consistency evaluation numbers (533 varieties of 588 enterprises, according to supplementary applications, the same below), 639 acceptance numbers were adopted this week (July) 25 to July 31), the enterprise consistency evaluation of drugs seems to have entered the intensive harvest period, 11 varieties of 10 enterprises piled up, many for the first;
review details of 11 varieties reviewed, Zhengda Qing added the first review variety this week, there are 11 varieties through consistency evaluation, of which 4 varieties for the first review, 4 varieties of the second review, 1 variety set together three, and 2 varieties respectively, the fourth and fifth review; 4 approved production, as if through consistency evaluation, more details are as follows table: this week's consistency evaluation of the details of the table cephalospora spore spore spore slow release tablets is the second generation of cephalosporine drugs, national Health Insurance drugs B, applicable to sensitive pathogens caused by the following infections: acute bronchitis and chronic bronchositis acute attack, pharyngitis, tonsillitis, pneumonia, sinus, supratic urinary tract infections.
the original research enterprise s.
pharmaceutical data show that there are 6 domestic market approvals of the current cephalosporine clique slow release tablets, involving 6 production enterprises, 2019 domestic sample hospital sales of 118 million yuan, of which Zhejiang Anlikang and Shandong Zibo Xinda Pharmaceutical accounted for the largest share, 28.98%, 26.57%, respectively;
worth mentioning is that only Zhejiang Anlikang Pharmaceutical declaration consistency evaluation and the first evaluation, to enhance product competitiveness at the same time, or will further eat into market share.
for missatin is a specific angiotensin II receptor (AT1 type) antagonist, is the only FDA and EMEA approved with comprehensive cardiovascular protection indications of ARB drug, is the plasma half-life of the longest vascular tension receptor blocker;
public data show that in 2017 only in China's public medical institutions terminal for misshatan tablet sales of more than 1 billion yuan, according to the pharmaceutical data enterprise version of the hospital sales data show that in 2019 for Mishadan tabletdomestic sample hospital sales of 415 million yuan, of which the original research enterprises accounted for 77.5%, import substitution is very inadequate, and it is known that the original research price is 3 to 5 times the price of domestic generic drugs.
the current for Mishatan film market approval has 53, involving 40 manufacturers, of which only 5 enterprises declared consistency evaluation was accepted, Shanghai Xinyi Tianping Pharmaceutical scored the first review, is expected to break down the original research barriers.
the consistency evaluation of the mischatan tablets to accept the details of the hydrochloric acid zositilline capsule zositilline is the only domestic antihistamine drug, the original development agent by UCB company in 2001 was first listed in Germany, after the United Kingdom, the United States, France and other countries listed.
at present, there are a variety of oral dosage forms of hydrochloric acid zositithityl, such as: tablets, granules, capsules, etc., of which hydrochloric acid left sitlily tablets have been evaluated by 6 enterprises, Hunan Jiuxian Pharmaceuticals, and it is worth mentioning is the hydrochloric acid zosititillin tablets for the whole country One of the second round of collected drugs, Hunan Jiuxian with 1.38 yuan / 5mg x 24 tablets of ultra-low price (equivalent to 0.057 yuan / piece) to remove the supply market in Beijing, Heilongjiang, Shanghai, Jiangsu, Anhui, Guangdong, Yunnan and other provinces.
is the first of Hunan's nine-year-old hydrochloric acid zositilline-exclusive-type hydrochloric acid zositilyquine capsules to complement the tablets through consistency evaluation, further consolidating its share of antihistamines drug market.
in addition, this week in Hunan Nine And the second home of sodium poop sodium intestinal tablets through consistency evaluation, can be described as a good thing.
adefovir capsule adefovir esters are clinically commonly used nucleoside anti-hepatitis B drugs.
original research enterprises for GlaxoSmithKline, listed in China in 2005, the current domestic adefovirest tablets and capsules two dosage forms, including the original research enterprises in the country has 7 manufacturers approved Adefoweeste capsule market approval.
according to the drug-intelligence consistency evaluation progress database shows that at present only Zhengda Qing and Beijing Shuangyi Pharmaceutical industry declared the consistency evaluation of the variety, is the first pass.
public data show that the domestic treatment of hepatitis B drugs are divided into interferon and nucleoside drugs.
of the nucleoside drugs accounted for about 80% of the market share, drug data show that in 2019 domestic sample hospital Adfowe ester capsule sample hospital sales reached 325 million yuan, of which more than 90% of the market share is occupied by Zhengda Qing, is now the first of the variety through consistency evaluation, further consolidate the market position of the variety.
hydrochloric acid cesalsion capsule hydrochloric acid rositin is a selective 5-serotonin (5-HT) and norepinephrine (NE) reuptake inhibitor, a neurosis medication for the nervous system and is suitable for the treatment of depression, widespread anxiety disorders, and chronic musculoskeletal pain.
, the original research enterprise selling to China in August 2006, was approved for import, the commodity is called XinBaida, sales in 2019 is 725 million U.S. dollars.
according to pharmaceutical data, the current domestic possession of the variety of approval number of the enterprise Chengdu Bete, the drug is pharmaceutical, and are in accordance with the new 4 categories of chemical drugs approved production, is now stone drug Europa followed, approved production at the same time as through consistency evaluation, successfully joined the queue of deer-by-deer research.
it is understood that the stone drug group generic drug consistency evaluation work into a dense harvest period, this year, has announced 9 varieties of 14 product regulations.
, 3 varieties of the first review, 4 varieties of the second review.
declaration acceptance of 12 varieties were contracted, injection with cephalosporine sodium declaration enterprises up to 19 this week CDE new consistency evaluation acceptance number 16 (12 varieties), of which 3 varieties for the first declared accepted varieties, respectively, Zhengda Pharmaceutical's osteosome three-milk soft gel, Shanghai Pharmaceuticals Chinese and Western Pharmaceuticals hydroxsophic chloride tablets, Tianjin Sino-New Pharmaceutical Group Co., Ltd.
this week's consistency evaluation report acceptance details of the injection consistency evaluation of the most competitive injection of cephalosporine sodium and injection of sodium pobutrazone added another competitor.
according to drug data, up to now 19 enterprises 52 injection with cephalosporine sodium acceptance number consistency evaluation number was hosted by CDE, is currently the injection consistency evaluation declaration acceptance number of the largest varieties;
data source: drug intelligence data, enterprise announcements and other network public data sources: drug intelligence network, enterprise announcements and other network public information.